Kineret Gets Rheumatologist Promotions From 35-Rep NPS Force
NPS will promote Amgen's rheumatoid arthritis agent Kineret to rheumatologists with a 35 member specialty sales force
You may also be interested in...
Amgen will keep IL-1 inhibitor Kineret (anakinra) for treatment of rheumatoid arthritis under a proposed consent agreement between Amgen and Federal Trade Commission that would allow the company's proposed acquisition of Immunex to proceed. FTC's July 12 announcement of the agreement notes that Kineret has had sales in excess of $2.4 mil. since its launch in November. The agreement would require the company to divest one of Immunex' marketed products, the neutrophil regeneration factor Leukine (sargramostim) (1"The Pink Sheet" Dec. 24, 2001, p. 16)...
Immunex' Leukine is available for licensing as part of Amgen's acquisition of the biotech company
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011